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invasive ( ≥ pT1) tumor growth (p = 0.016). In patients with 
invasive tumors a significant increase of the G allele was 
found (T/T vs. T/G + G/G; p = 0.023; OR 2.203, 95% CI 1.111–
4.369).  Conclusion: These data indicate that the G-variant of 
the  Mdm2 SNP309 might influence the development of a 
more aggressive tumor phenotype in patients with bladder 
cancer without affecting the overall tumor risk. 
 © 2013 S. Karger AG, Basel 
 Introduction 
 One major regulator of the p53 network is the human 
mouse double minute 2 protein (Mdm2). The  Mdm2 
gene is located on chromosome 12q14.3-q15 and encodes 
an E3 ubiquitin ligase that is involved in p53 degradation 
by negatively regulating p53 stability and transcriptional 
activity  [1] .  Mdm2 gene (amplification) or protein (over-
expression) alterations can frequently be found in various 
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 Abstract 
 Objective: Human mouse double minute 2 (Mdm2) is essen-
tial in degrading p53 by acting as an ubiquitin ligase and 
therefore plays a vital role in cell cycle and survival. The G-
variant of the  Mdm2 SNP309, which is located within the pro-
moter of the  Mdm2 gene, increases expression of Mdm2 and 
thereby inhibits the p53 pathway. Several studies have in-
vestigated the influence of this SNP on disease risk and onset 
of various malignancies. The impact of  Mdm2 SNP309 on 
bladder cancer is still to be established due to inconsistent 
data.  Methods: In a case-control study we determined the 
distribution of  Mdm2 SNP309 genotypes in 111 patients with 
an early-onset bladder cancer (diagnosis <45 years of age), 
in 113 consecutive bladder cancer patients and in a control 
group consisting of 140 patients without any malignancy. 
 Results: There was no significant association between the 
allelic distribution of the  Mdm2 SNP309 and tumor risk, early 
onset, gender or grade of the tumor. According to tumor 
stage we found a significant difference in the distribution of 
the  Mdm2 SNP309 between patients with noninvasive and 
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cancer types, including bladder cancer  [2, 3] . A single nu-
cleotide polymorphism (SNP) in the promoter region of 
the  Mdm2 gene at position 309 ( Mdm2 SNP309; T<=>G) 
has been broadly investigated because the G allele binds 
transcriptional activator Sp1 in a more effective way than 
the T allele, therefore generating higher levels of Mdm2 
RNA and protein  [4] . This might accelerate tumorigen-
esis by degrading p53. An influence of this SNP on cancer 
risk was shown for various tumor types in different popu-
lations  [5] . In addition, this SNP might also affect the age 
of disease onset, especially in patients with Li-Fraumeni 
syndrome, or even gender-specific cancer risk  [4, 6, 7] .
 Only very inconsistent data are available for the role of 
the  Mdm2 SNP309 in bladder cancer. To date three case-
control studies have been published. Horikawa et al.  [8] 
reported no influence of this SNP on bladder cancer risk. 
Onat et al.  [9] found an increased tumor risk for the ho-
mozygous GG-variant, whereas Gangwar and Mittal  [10] 
reported a reduced bladder cancer risk for individuals 
with the homozygous GG-variant. Regarding disease out-
come, ambiguous data have been published too. While 
Sanchez-Carbayo et al.  [11] reported a poorer overall sur-
vival of patients with the homozygous TT-variant com-
pared to patients with a least one risk allele, Horikawa et 
al.  [8] found a longer recurrence-free survival in patients 
with the homozygous wild-type genotype. Recently, a 
study focusing on stage pT1 bladder tumors found no in-
fluence of the SNP on prognosis  [12] . 
 Interestingly, the  Mdm2 SNP309 might also have an 
influence on the survival of bladder cancer patients treat-
ed with chemoradiotherapy. In a study by Shinohara et al. 
 [13] patients with at least one risk allele had an improved 
cancer-specific survival rate after therapy compared to 
patients carrying the wild-type allele only. However, this 
positive effect of the risk allele could not be validated in a 
second, similar study  [14] . To advance the still ongoing 
discussion of the role of the  Mdm2 SNP309 on bladder 
cancer risk we performed a case-control study including 
a subset of patients with early disease onset.
 Materials and Methods 
 Patients and Tissue Samples 
 Two hundred and twenty-four formalin-fixed and paraffin-em-
bedded tissue samples from bladder cancer patients were investi-
gated and compared to 144 samples from a control group of pa-
tients without any malignancy acquired at the Department of Urol-
ogy, University of Regensburg. The tumor group consisted of two 
subgroups: a consecutive group of bladder cancer patients (n = 113) 
and a patient cohort with early-onset bladder cancer (less than 45 
years of age at diagnosis, n = 111). All patients were Caucasians.
 The tumors were diagnosed according to the WHO classifica-
tion of bladder tumors and staged according the TNM system  [15, 
16] . All available slides were reinvestigated by one surgical pathol-
ogist (A.H.) and all tumors were histologically classified as transi-
tional cell carcinomas. Cases with missing data (e.g. tumor stage, 
gender) were used for risk evaluation in the case-control study, but 
were excluded from statistical analyses concerning single param-
eter tests. All tumors were primary tumors. Characteristics of the 
study participants are shown in  table 1 . Institutional review board 
approval was obtained for the study.
 Tissue Microdissection and DNA Isolation 
 DNA for the study was extracted from normal bladder tissue 
(microdissection from serial sections) using the High Pure PCR 
Template Preparation Kit (Roche GmbH, Mannheim, Germany) 
according to the manufacturer’s instructions. 
 Analysis of Mdm2 SNP309 
 To analyze the genotype of the  Mdm2 SNP309 restriction frag-
ment length polymorphism (RFLP) analysis was performed. 
When the G allele was present the region of interest contained an 
 Msp A1l site (5 ′ -CMGCKG-3 ′ ). The G allele therefore resulted in 
digestion of the PCR product (157 bp  ≥ 106 + 51 bp) whereas PCR 
products harboring the T allele in SNP309 remained unaffected 
(157 bp).
 Amplification of Promoter Region and RFLP Analysis 
 The  Mdm2  SNP309 region was amplified by using PCR prim-
ers (5-FAM-sense: 5 ′ -CGCGGGAGTTCAGGGTAAAG-3 ′ ; anti-
sense: 5 ′ -CTGAGTCAACCTGCCCACTG-3 ′  [17] ) obtained from 
Table 1.  Characteristics of study patients
Control 
group
Consecutive 
tumor group
Early-onset 
tumor group
n 140 113 111
Age, years
Median
Mean
Range
68
66.9
17–89
69
68.6
37–93
39
37.6
18–45
Stage, n
Ta
T1
≥T2
Unknown
68
29
13
3
49
10
14
38
Grading, n
G1
G2
G3
Unknown
39
44
30
0
24
29
16
42
Gender, n
Male
Female
Unknown
120
12
8
90
22
1
64
24
23
 Mdm2 SNP309 in Bladder Cancer Pathobiology 2014;81:53–59
DOI: 10.1159/000355976
55
Metabion (Martinsried, Germany) in a total volume of 25 μl 
 containing 100 ng DNA, 0.15 μ M primers, 0.2 m M dNTP (Roche 
Diagnostics) and 0.0025 U/μl GoTaq (Promega, Mannheim, 
 Germany). The thermal cycling conditions were as follows: initial 
denaturation for 3 min at 95  °  C, 35 cycles of denaturation at 95  °  C, 
annealing at 61  °  C for 1 min, elongation at 72  °  C for 1 min and final 
primer extension at 72   °   C for 10 min. PCR products were incu-
bated overnight with 5 U  Msp A1I (New England Biolabs, Frank-
furt am Main, Germany) and 100 μg/ml BSA at 37   °   C in a total 
volume of 30 μl to ensure complete digestion. Capillary electro-
phoresis using an ABI PRISM 310 (Applied Biosystems, Foster 
City, Calif., USA) genetic analyzer was used to separate restriction 
fragments. Analyses were done using GeneScan ® analysis soft-
ware. Ten randomly selected cases were also sequenced to verify 
the RFLP results. 
 Statistical Analysis 
 Publicly available software (http://ihg.gsf.de/cgi-bin/hw/hwa1.
pl) was used to determine if genotype distribution followed the 
Hardy-Weinberg equilibrium, whereas χ 2 statistics (two-sided 
Fisher’s exact test or Pearson’s where appropriate) were used to 
evaluate case-control differences in the distribution of genotypes 
and to analyze associations between clinical or histopathological 
characteristics and genotype. Statistical analysis was done utilizing 
the Statistical Package for the Social Sciences (SPSS) version 13.0 
(SPSS, Chicago, Ill., USA). p values <0.05 were interpreted as sta-
tistically significant.
 Results 
 The genotype distribution followed the Hardy-Wein-
berg equilibrium in cases (early-onset tumor group, p = 
0.342, and consecutive tumor group, p = 0.443) and con-
trols (p = 0.594). Nine cases were randomly selected to 
verify RFLP analyses: these cases were sequenced and 
showed a 100% concordance between both methods 
( fig. 1 ).
 In order to ensure the usage of our control group as a 
representative Caucasian cohort we compared the  Mdm2 
SNP309 distribution from our cohort with published 
control cohorts from other studies. A very similar allelic 
distribution was seen in all 4 studies underlining the use 
of a nonbiased control group in our study ( fig. 2 ). 
 There were no significant differences in the distribu-
tion of the allelic variants of the  Mdm2 SNP309 between 
controls and cases (neither analyzed separately nor ana-
lyzed as one cohort;  table 2 ;  fig. 3 a, b). Regarding tumor 
stage, there was a remarkable difference in genotype dis-
 Fig. 1. Representative example of the 
 MDM2 SNP309 RFLP analysis. In the up-
per lane only the undigested PCR product 
(157 bp) is visible after the digest resulting 
from a T/T genotype of the sample. In the 
middle lane the undigested (157 bp) and the 
digested (51 bp) products are visible indi-
cating a heterozygous T/G genotype of the 
sample. The 106 bp product which is also 
created by the RFLP analysis is not visible 
due to the 5 ′ end labeling of the PCR prod-
uct. In the lower lane only the 51 bp product 
is visible after the digest suggesting a G/G 
genotype of the sample. The added results 
from the Sanger sequencing confirmed the 
results from RFLP analyses (arrows). 
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 Fig. 2. Distribution of the  MDM2 SNP309 in control cohorts from 
Caucasian studies. The allele frequencies were very similar to the 
control cohort from this study. 
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tribution which did not reach statistical significance 
( table 3 ). After grouping the cases into the biological rel-
evant categories of noninvasive (stage pTa) and invasive 
(stage  ≥ pT1) tumors, there was a significant difference in 
genotype distribution with a significant increase of the 
risk allele G in patients with invasive bladder cancer 
 ( table 3 ;  fig. 4 ). No significant differences in genotype dis-
tribution were found for tumor grade, gender and age of 
the patients (data not shown).
 In order to enlarge the statistical power of the avail-
able analyses on the  MDM2 SNP309 we combined all 
available data from Caucasian bladder cancer studies 
to perform a meta-analysis. By doing this SNP data from 
243 controls and 581 bladder cancer patients were avail-
able  [9, 11, 12,  this study]. The genotype distribution 
followed the Hardy-Weinberg equilibrium in controls 
(p = 0.234) and cases (p = 0.444). The distribution of 
the allelic variants did not differ significantly between 
controls  and cases ( fig.  5 ). There was also no signifi-
cant  difference in the distribution of the G allele be-
tween the two  cohorts (p = 0.713; OR 0.942, 95% CI 
0.686–1.294). 
Table 2.  Distribution of allelic variants between the investigated groups
Control 
group
Consecutive 
tumor group
Early-onset 
tumor group
Comparison
p value
OR 95% CI
Genotype
T/T
T/G
G/G
51 (36.4)
70 (50.0)
19 (13.6)
40 (35.4)
51 (45.1)
22 (19.5)
35 (31.5)
50 (45.0)
26 (23.5) 0.371
Tumor groups combined1
Genotype
T/T
T/G
G/G
51 (36.4)
70 (50.0)
19 (13.6)
75 (33.5)
101 (45.1)
48 (21.4) 0.173
T/T
T/G + G/G
51 (36.4)
89 (63.6)
75 (33.5)
149 (66.5)
0.573 1.138 0.732–1.771
Values are n with percentage in parentheses. 
1 Results of the consecutive and early-onset tumor groups together.
p = 0.371
Control
group
100
%
a
90
80
70
60
50
40
30
20
10
0 Consecutive
tumor group
Early onset
group
G/G
T/G
T/T
50.0
13.6
45.1
19.5
45.0
23.5
36.4 35.4 31.5
b
p = 0.174
Control group
100
%
90
80
70
60
50
40
30
20
10
0 Combined
tumor group
G/G
T/G
T/T
50.0
13.6
45.1
21.4
36.4 33.5
 Fig. 3. Distribution of the  MDM2 SNP309 variants in our cohorts.  a Results for both tumor cohorts (consecutive and early-onset pa-
tients).  b Results for the grouped tumor cohort. No significant differences were found in both analyses.  
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 Discussion  
 In the present study we analyzed the distribution of the 
 Mdm2 SNP309 in a Caucasian cohort of bladder cancer pa-
tients and a control group without any malignancy. To our 
knowledge our study comprised the largest cohorts in a 
Caucasian case-control study to date. Our data showed that 
the  Mdm2 SNP309 did not influence the overall risk for 
bladder cancer. These data are in line with a study by Hori-
kawa et al.  [8] that analyzed large cohorts in a Japanese case-
control study. In addition, the results from a meta-analysis 
performed with all available data from studies on Cauca-
sian cohorts further strengthened our data. Contrary to our 
results, two studies showed contradicting effects of the G-
variant of the SNP. These discrepancies to our study might 
be explained by a small number of cases analyzed (n = 75) 
 [9] or population-based genetic variation  [10] . To date no 
additional case-control studies have been published and a 
combined analysis of all the available data might be biased 
by the different ethnical background of the cohorts. 
 Of great interest was the study by Sanchez-Carbayo et 
al.  [11] that described an influence of the  Mdm2 SNP309 
Table 3.  Distribution of Mdm2 SNP309 genotype according to tumor stage
Tumor group T/T T/G G/G Comparison
p value
OR 95% CI
Stage
0.071
Ta 46 (39.3) 47 (40.2) 24 (20.5)
T1 8 (20.5) 25 (64.1) 6 (15.4)
≥T2 7 (25.9) 16 (59.3) 4 (14.8)
Ta (noninvasive) 46 (39.3) 47 (40.2) 24 (20.5) 0.016
≥T1 (invasive) 15 (22.7) 41 (62.1) 10 (15.2)
T/G + G/G
Ta (noninvasive) 46 (39.3) 71 (60.7) 0.023 2.203 1.111–4.369
≥T1 (invasive) 15 (22.7) 51 (77.3)
Values are n with percentages in parentheses. Bold values are significant.
p = 0.023
Non-invasive
tumor-growth
100
%
90
80
70
60
50
40
30
20
10
0 Invasive
tumor-growth
T/G + G/G
T/T
60.7
77.3
39.3
22.7
p = 0.301
Controls
100
%
90
80
70
60
50
40
30
20
10
0 Bladder cancer patients
G/G
T/G
T/T
52.3
14.8
47.2
18.5
32.9 34.3
 Fig. 4. Distribution of the G allele of the  MDM2 SNP309 in patients 
with noninvasive and invasive bladder tumors. A significant in-
crease of the G-variant was revealed in patients with invasive blad-
der cancer. 
 Fig. 5. Meta-analysis of the genotype distribution of the  MDM2 
SNP309 in Caucasians. Results from all available studies on blad-
der cancer were combined. No significant difference in genotype 
distribution was found. 
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on disease onset in bladder cancer patients, especially in 
the group of patients with superficial tumors. Our data 
were contradicting to these findings as we found no as-
sociation between allelic variants and disease onset, al-
though we analyzed a large subgroup of young bladder 
cancer patients. These discrepancies might be explained 
by the fact that the patient cohort from the Sanchez-Car-
bayo study that showed the age-associated effect in geno-
type distribution had a mean age of approximately 60 
years. As the median age for bladder cancer patients is 
about 69 years these patients with early disease onset were 
still within a normal age range  [21] . In addition, the study 
by Sanchez-Carbayo et al.  [11] grouped patients with tu-
mor stages pTa and pT1 as patients with superficial dis-
ease. This grouping might not reflect the biological back-
ground of the tumors, as mRNA expression analyses 
clearly revealed a very close proximity in the expression 
profiles of pT1 and muscle-invasive pT2 bladder tumors. 
The profiles of pTa tumors clearly separated from the in-
vasive tumors  [22] . Therefore, a grouping of noninvasive 
and invasive tumors could bias the results and skew as-
sociations between analyzed groups. This grouping 
should be avoided.
 The results from our study suggested a higher risk for 
individuals carrying the risk allele G for developing an 
invasive bladder tumor. From these data one might sug-
gest that the higher rate of MDM2 transcription caused 
by the SNP309 G-variant could be causative for this more 
aggressive phenotype of bladder cancer. However, high 
expression of MDM2 in bladder tumors was shown to be 
associated with a better progression-free and a better 
overall survival of the patients  [23] . Moreover, high ex-
pression of MDM2 was also associated with low-stage 
and low-grade bladder tumors  [24] . These data strength-
en our findings that the G-variant of the SNP309 was not 
a general risk factor for bladder cancer as a higher MDM2 
expression seemed not to support the development of ag-
gressive bladder cancer per se. Functional studies also 
showed that MDM2 inhibits the hTR promoter and can 
therefore regulate telomerase activity in bladder cancer 
cell lines  [25] . This regulatory ability of MDM2 is anoth-
er hint for a quite protective role of MDM2. Nevertheless, 
high MDM2 levels in tumor cells are a risk factor for an 
aggressive disease if p53 accumulation is simultaneously 
present in the cells. Several studies have shown that con-
current MDM2 and p53 overexpression was correlated 
with disease progression and shorter survival in bladder 
cancer patients  [26, 27] . As p53 accumulation is mainly 
caused by mutations it might be speculated that high lev-
els of MDM2 inactivate the remaining wild-type p53 in 
p53-mutated cells, as was suggested for individuals with 
Li-Fraumeni syndrome  [28] . In bladder cancer, p53 mu-
tations were mainly described in carcinoma in situ and 
invasive tumors, but these alterations were also found in 
preneoplastic lesions of the urothelium  [29, 30] . There-
fore, the G-variant of the  MDM2 SNP309 might trigger 
the development of a more aggressive bladder cancer dis-
ease as soon as p53 alterations occur, and the combina-
tion of both events could promote invasive tumor growth. 
But as the functional proof for this model has not yet been 
adduced in bladder cancer, this theory remains specula-
tive.
 In conclusion, our study showed that the  MDM2 
SNP309 has no influence on bladder cancer risk in Cau-
casians. The G-variant of the SNP was associated with 
invasive tumor growth and might predispose for the de-
velopment of a more aggressive phenotype on bladder 
cancer compared to individuals carrying the T allele only. 
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